Category Archives: Cancer Treatment

The Role of Eric Lefkofsky in Cancer Research

Published / by TheHI

Eric Lefkofsky is a businessman and a technological expert. He among his partners are the brain behind the Tempus Inc. He is also the chief executive officer of this company. In this establishment, he has been pooling resources together in an attempt to realize a more effective treatment to those with cancer. Eric has been an investor in various sectors of the economy. He has been one of the founding partners at the Light bank; a company that focuses on disruptive technological projects.

Eric Lefkofsky is a graduate of Lathrup High school. He then proceeded to the Michigan University where he undertook a degree in law. In the year 1991, he graduated with honors. He went ahead to enroll for post graduate studies in the same University. He was conferred with a Juris doctorate in the year 1993.

As the president of the Tempus Company, Eric Lefkofsky primary role is the implementation of ideas and resolutions passed during board meetings. As a CEO, he oversees a research project that it is aimed at discovering the best treatment plans for the cancerous patients.

Unlike other research organizations, Tempus Inc. takes a different approach to the subject matter. Instead of striving to get a single ultimate cure, the research focuses on giving a variety of options that together lead to the same goal. In this way, the group equips various medical doctors with a range of choices on how to best treat a cancerous patient. To achieve this target, the firm makes use of personalized treatment plans and available data from various practicing doctors across the globe. Tempus Inc. then uses the molecular therapy concept to analyze the data and make any recommendation.

For the firm to make a concrete and valuable recommendation, Tempus Inc. collects larger samples of genomic data for analysis. The analysis takes into consideration various options that the doctor can apply. An algorithm is introduced to come up with the best possible option given the circumstance. The result is real-time analysis of data leading to better care services for the patients. The program is even made easier courtesy of the various patients who have been working with the program. The firm hopes that patients with all forms of cancer will be able to appreciate its initiative.

About Eric Lefkofsky :

Oncotarget Journal

Published / by TheHI

Oncotarget is an insightful journal that is growing too fast due to its high demand in publishing a wide range of online papers on a weekly basis. Oncotarget is a privately owned publishing firm with close to 50 employees. The Journal promotes scientific researches with a core objective of creating a disease-free world. The publishing firm is well committed to making available scientific results to a wide population of people across the United States and the globe. The organization chose to share their scientific researches through online publishing because of easy accessibility and the significant rise in a number of people accessing the internet lately.

Oncotarget, the international peer reviewed journal, focuses on the pathological basis of all types of cancer, potential targets for therapy, and cancer management programs. Many at times, people lack basic information on some of the deadly diseases like cancer. Oncotarget has gone an extra mile to bring to the surface all the information one has to know to stay safe from cancer infections. The journal does a good job in educating people because it also seeks to bring acceptance to those suffering from cancer infections by embracing professional health care.Unlike other online journals, Oncotarget is a multidisciplinary traditional journal with a free access. For instance, some of the topics covered in the journal include; Oncology, Aging Pathology, Immunology, Microbiology, Cell death, Autophagy, and chromosome.

With four years of operation, Oncotarget has invested heavily on research publication by working with competent editorial boards of health professionals and various scientists across the globe. The journal has been able to reach many people because it is available on the Dove Press and other influential internet sites. Additionally, their platform allows people accessing their journals an opportunity to air their ideas which in the long run helps them to make sound decisions and solutions. Actually, Oncotarget is among the few publishing firms that believe in a free information sharing society.Widely recognized as a platform that deals with analysis, treatment, and prevention of deadly diseases like Cancer, Oncotarget has so far received three awards; PubMed and PMC, Web of Science, and Scopus: Ranks Q1. Finally, due to their constructive and insightful nature, Oncotarget was ranked first among those journals publishing oncology content in the United States in the year 2015.

Eric Lefkofsky’s Fight Against Cancer

Published / by TheHI

Cancer is one of the top killer diseases in the world. While there currently is no cure for cancer, scientists have developed several ways of containing and treating the condition. Eric Lefkosfksy, the CEO and co-founder of Tempus, argues that for a successful cancer treatment plan, doctors must have access to data.

The Argument For Data and Cancer Treatment

There is overwhelming patient data but a lack of resources to combine genomic information with this data. Speaking at the “Fortune” Brainstorm Health Conference (San Diego), Lefkofsky noted that there was a need to combine both clinical and molecular data to develop an effective treatment for cancer. This means that apart from gathering information on a patient’s RNA and DNA makeup, clinicians should be aware of the treatments that patients are using and their response to these treatments.

Lefkofsky motivated to establish Tempus the time his wife got diagnosed with cancer. It was during this time that Lefkofsky noted that drivers had better access to data on how to perform their jobs than oncologists. He noted that in most cases, oncologists have no data on how a treatment affects a certain group of patients.

Tempus is based on the concept of introducing a technology that surpasses the current pathology and electronic medical record systems. The technology helps scientists to gather data, clean it, and feed this renewed version to the original source for verification and validation. But the large aggregate of data consisting of all patient data may be used to access how certain treatments work.Lefkofsky’s goal is to have oncologists andneuro-scientists use the Tempus platform for fetching data for analysis.

About Eric Lefkofsky

Eric Lefkofsky is the CEO and co-founder of Tempus. This is a technology firm that has created  operating system for battling cancer. He has also contributed to the establishment of many prosperous companies including Lightbank, Groupon, Uptake Technologies, Mediaocean, EchoGlobal Logistics, and Inner Workings.

In 2006, Lefkofsky partnered with his wife to establish a private charity, Lefkofsky Family Foundation. The charity aims at enhancing the lives of disadvantaged people in the society. Lefkofsky is also involved in many charity initiatives including; “Lurie Children’s Hospital”(Chicago), “The Museum of Science”, and “The Art Institute of Chicago”.

Learn More: